July 20, 2017, Modi’in – Silenseed announced the FDA approval of IND (Investigational New Drug) for Phase 2 Clinical Trial of siG12D-LODER in the Treatment of Patients with Unresectable Locally Advanced Pancreatic Cancer

The trial is planned as a Prospective, Multinational, Multi-center, Phase 2, Randomized, Controlled, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of siG12D-LODER in the Treatment of Patients with Unresectable Locally Advanced Pancreatic Cancer (LAPC) when used in Conjunction with Standard Chemotherapy (NCT01676259).